Championing Pediatric Patients
Created by Congress in 2007- and Administered by the U.S. Food and Drug Administration (FDA) - the Rare Pediatric Disease Priority Review Voucher (PPRV) provides vital certainty to innovators and delivers lifesaving treatments and hope to millions of families across the U.S. The PPRV serves as a powerful incentive to stimulate the development of therapies for diseases that are not economically viable to pursue - and does so at no direct cost to taxpayers.
Despite strong bipartisan backing, the program’s authorization lapsed in December 2024, halting a vital incentive for drug developers who have historically relied on it to advance novel treatments for rare pediatric diseases.
The Cost of PRV Inaction
The PRV program offers hope to children with few or no treatment options. It serves as a powerful incentive to stimulate the development of therapies for diseases that are not economically viable to pursue - and does so at no direct cost to taxpayers.
Watch: The Impact of the PRV
Meet the courageous children living with rare diseases whose lives have been changed by access to treatments - and hope - made possible through the PRV program.
